Oncolinx is developing the next generation of antibody-drug conjugates (ADCs)--powerful, targeted cancer therapies that are more effective and have dramatically fewer side effects than current methods of cancer treatment. These therapies can be targeted to nearly any type of cancer and are rapidly becoming the state-of-the-art in cancer treatment. Drawing on the scientific innovation of the National Cancer Institute, the world's leading biotechs and life sciences companies, Oncolinx is redefining the paradigm of cancer therapy.
Location: United States, Massachusetts, Boston
Employees: 1-10
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | 43North | 43north.or... |
| - | MassChalle... | masschalle... |
Mentions in press and media 3
| Date | Title | Description |
| 14.11.2016 | Why These Boston Startups Will Be Moving to Buffalo for a Year | 43North, part of New York Governor Andrew Cuomo's Buffalo Billion project, recently announced the winners of its 2016 competition. And why would we care about a startup contest in Upstate New York? Normally, we wouldn't. This year, though, ... |
| 29.10.2014 | MassChallenge Celebrates Highest-Impact Startups from 2014 | MassChallenge and ~1,700 members of the Boston startup community gathered to celebrate entrepreneurship at the fifth-annual MassChallenge Awards Ceremony. The event featured pitches from the Top 26 startups, and speeches from Governor Deval... |
| 14.10.2014 | MassChallenge Announces Top 26 Finalists from Most Competitive Class Ever | Our entrepreneurs had a rigorous summer and Im very proud of all startups from the 2014 class, said MassChallenge Founder and President Akhil Nigam. These top 26 startups are poised to make a tremendous impact across a variety of industries... |